Acute Pericarditis - Explore the Science & Experts | ideXlab


Scan Science and Technology

Contact Leading Edge Experts & Companies

Acute Pericarditis

The Experts below are selected from a list of 3162 Experts worldwide ranked by ideXlab platform

Acute Pericarditis – Free Register to Access Experts & Abstracts

Massimo Imazio – One of the best experts on this subject based on the ideXlab platform.

  • national trends of Acute Pericarditis post atrial fibrillation ablation
    International Journal of Clinical Practice, 2020
    Co-Authors: Fahed Darmoch, Chadi M Alraies, Yasser Alkhadra, Homam Moussa Pacha, Mohamad Soud, Tarek Chami, Massimo Imazio, Allan L Klein

    Abstract:

    BACKGROUND Atrial fibrillation ablation increased over the last two decades by its high success rate. However, the trend of inpatient adverse outcomes is limited. The aim of this study to examine the frequency and predictors of Acute Pericarditis resulting from catheter ablation. METHODS Using the National Inpatient Sample, we identified all patients who underwent AF ablation. Univariate and multivariate logistic regressions were performed for the primary outcome of in-hospital Acute Pericarditis post-AF ablation. Variance-weighted regression has been used to test for linear and curvilinear trends in disease characteristics and outcomes over time. RESULTS From 2002 to 2014, our study included 122,993 patients, Acute Pericarditis was found in 984 (0.8%) patients who underwent AF ablation. The trend of Acute Pericarditis showed inconsistent fluctuation leaning towards reduction over the years. Multivariate analysis showed that patients of female gender are at a 40% higher risk of Acute Pericarditis post-ablation compared with males. Additionally, obese patients have a 40% higher risk of developing Acute Pericarditis compared with patients who have BMI < 30. Furthermore, anaemia and rheumatoid arthritis have the odds ratio (OR: 2.63; 95% [CI] 2.04-3.39) and (OR: 1.64; 95% [CI] 1.08-2.48). CONCLUSION Post-AF ablation, in-hospital Acute Pericarditis showed inconsistent fluctuation leaning towards reduction. Female gender and obesity are at higher risk for developing Acute Pericarditis post-AF ablations. Proper evaluation might alter those complications.

    Free Register to Access Article

  • National trends of Acute Pericarditis post‐atrial fibrillation ablation
    International journal of clinical practice, 2019
    Co-Authors: Fahed Darmoch, Homam Moussa Pacha, Mohamad Soud, Tarek Chami, Massimo Imazio, M. Chadi Alraies, Yasser Al-khadra, Allan L Klein

    Abstract:

    BACKGROUND Atrial fibrillation ablation increased over the last two decades by its high success rate. However, the trend of inpatient adverse outcomes is limited. The aim of this study to examine the frequency and predictors of Acute Pericarditis resulting from catheter ablation. METHODS Using the National Inpatient Sample, we identified all patients who underwent AF ablation. Univariate and multivariate logistic regressions were performed for the primary outcome of in-hospital Acute Pericarditis post-AF ablation. Variance-weighted regression has been used to test for linear and curvilinear trends in disease characteristics and outcomes over time. RESULTS From 2002 to 2014, our study included 122,993 patients, Acute Pericarditis was found in 984 (0.8%) patients who underwent AF ablation. The trend of Acute Pericarditis showed inconsistent fluctuation leaning towards reduction over the years. Multivariate analysis showed that patients of female gender are at a 40% higher risk of Acute Pericarditis post-ablation compared with males. Additionally, obese patients have a 40% higher risk of developing Acute Pericarditis compared with patients who have BMI 

    Free Register to Access Article

  • Acute Pericarditis: Management Overview
    Myopericardial Diseases, 2016
    Co-Authors: Massimo Imazio

    Abstract:

    Acute Pericarditis is the most common pericardial syndrome that is encountered in clinical practice. It is an inflammatory pericardial syndrome with or without pericardial effusion [1, 2].

    Free Register to Access Article

Rita Trinchero – One of the best experts on this subject based on the ideXlab platform.

  • Colchicine for Acute Pericarditis. Results from the Investigation on Colchicine in Acute Pericarditis (ICAP). A prospective, randomized, double-blind, placebo-controlled, multicenter trial
    European Heart Journal, 2013
    Co-Authors: Massimo Imazio, Antonio Brucato, Riccardo Belli, Rita Trinchero, Roberto Cemin, Stefania Ferrua, Stefano Maggiolini, D. H. Spodick, Yehuda Adler

    Abstract:

    Purpose: Despite a large amount of data on recurrent Pericarditis, conclusive data are lacking to demonstrate the efficacy and safety of colchicine for the treatment of the first attack of Acute Pericarditis. The Investigation on Colchicine in Acute Pericarditis (ICAP) trial is a prospective, randomized, double-blind, placebo-controlled, multicenter trial aimed at the evaluation of the efficacy and safety of colchicine to treat Acute Pericarditis and prevent its recurrences.

    Methods: Eligible adult patients with Acute Pericarditis were randomly assigned to placebo or colchicine (0.5 mg twice daily for 3 months for patients>70kg or 0.5 mg once daily if ≤70kg) in addition to conventional anti-inflammatory therapy with aspirin or ibuprofen in a multicenter, double-blind, placebo-controlled trial. The primary study outcome was incessant/recurrent Pericarditis within 18 months. Secondary outcomes were symptoms persistence at 72 hours, remission within 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and constrictive Pericarditis.

    Results: Of the 240 randomly assigned participants (mean age 52.1±16.9 years, 60% males), 65 patients (27.1%) reached the primary outcome: incessant/recurrent Pericarditis within 18 months was 16.7% in the colchicine group and 37.5% in the placebo group (relative risk reduction 0.56 95% CI 0.30-0.72; number needed to treat-NNT 4). Colchicine reduced symptoms persistence at 72 hours (respectively, 19.2% vs. 40.0%; p=0.001), number of recurrences, hospitalizations (respectively, 5.0% vs. 14.2%; p=0.016), improved the remission rate at 1 week (respectively, 85.0% vs. 58.3%; p

    Free Register to Access Article

  • colchicine for Acute Pericarditis results from the investigation on colchicine in Acute Pericarditis icap a prospective randomized double blind placebo controlled multicenter trial
    European Heart Journal, 2013
    Co-Authors: Massimo Imazio, Antonio Brucato, Riccardo Belli, Rita Trinchero, Roberto Cemin, Stefania Ferrua, Stefano Maggiolini, D. H. Spodick, Yehuda Adler

    Abstract:

    Purpose: Despite a large amount of data on recurrent Pericarditis, conclusive data are lacking to demonstrate the efficacy and safety of colchicine for the treatment of the first attack of Acute Pericarditis. The Investigation on Colchicine in Acute Pericarditis (ICAP) trial is a prospective, randomized, double-blind, placebo-controlled, multicenter trial aimed at the evaluation of the efficacy and safety of colchicine to treat Acute Pericarditis and prevent its recurrences.

    Methods: Eligible adult patients with Acute Pericarditis were randomly assigned to placebo or colchicine (0.5 mg twice daily for 3 months for patients>70kg or 0.5 mg once daily if ≤70kg) in addition to conventional anti-inflammatory therapy with aspirin or ibuprofen in a multicenter, double-blind, placebo-controlled trial. The primary study outcome was incessant/recurrent Pericarditis within 18 months. Secondary outcomes were symptoms persistence at 72 hours, remission within 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and constrictive Pericarditis.

    Results: Of the 240 randomly assigned participants (mean age 52.1±16.9 years, 60% males), 65 patients (27.1%) reached the primary outcome: incessant/recurrent Pericarditis within 18 months was 16.7% in the colchicine group and 37.5% in the placebo group (relative risk reduction 0.56 95% CI 0.30-0.72; number needed to treat-NNT 4). Colchicine reduced symptoms persistence at 72 hours (respectively, 19.2% vs. 40.0%; p=0.001), number of recurrences, hospitalizations (respectively, 5.0% vs. 14.2%; p=0.016), improved the remission rate at 1 week (respectively, 85.0% vs. 58.3%; p<0.001), and prolonged time to first recurrence. Corticosteroid use (OR 4.17, 95% CI 1.28 to 13.53; p=0.018), and C-reactive protein elevation at presentation (OR 3.15, 95% CI 1.05 to 9.49; p=0.041) were independent risk factors for recurrences in multivariable analysis. Overall adverse effect rates were similar in the study groups (respectively, 11.7% in the colchicine group and 10.0% in the placebo group; p=0.836) as well as withdrawal rates (respectively, 11.7% vs. 8.3%; p=0.519). No serious adverse effects were observed. Conclusions: The ICAP trial is the first multicenter, double-blind, randomized trial to show the efficacy and safety of colchicine as an adjunct to conventional anti-inflammatory therapy to halve incessant/recurrent Pericarditis within 18 months, reduce the number of recurrences, and prolong the time to subsequent recurrence after a first episode of Acute Pericarditis.

    ClinicalTrials.gov [NCT00128453][1].

    [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00128453&atom=%2Fehj%2F34%2Fsuppl_1%2F877.atom

    Free Register to Access Article

  • Risk of Constrictive Pericarditis After Acute Pericarditis
    Circulation, 2011
    Co-Authors: Massimo Imazio, Antonio Brucato, Silvia Maestroni, Davide Cumetti, Riccardo Belli, Rita Trinchero, Yehuda Adler

    Abstract:

    Background—Constrictive Pericarditis (CP) is considered a rare, dreaded possible complication of Acute Pericarditis. Nevertheless, there is a lack of prospective studies that have evaluated the specific risk according to different etiologies. The aim of this study is to evaluate the risk of CP after Acute Pericarditis in a prospective cohort study with long-term follow-up. Methods and Results—From January 2000 to December 2008, 500 consecutive cases with a first episode of Acute Pericarditis (age, 51±16 years; 270 men) were prospectively studied to evaluate the evolution toward CP. Etiologies were viral/idiopathic in 416 cases (83.2%), connective tissue disease/pericardial injury syndromes in 36 cases (7.2%), neoplastic Pericarditis in 25 cases (5.0%), tuberculosis in 20 cases (4.0%), and purulent in 3 cases (0.6%). During a median follow-up of 72 months (range, 24 to 120 months), CP developed in 9 of 500 patients (1.8%): 2 of 416 patients with idiopathic/viral Pericarditis (0.48%) versus 7 of 84 patients…

    Free Register to Access Article

Yehuda Adler – One of the best experts on this subject based on the ideXlab platform.

  • Colchicine for Acute Pericarditis. Results from the Investigation on Colchicine in Acute Pericarditis (ICAP). A prospective, randomized, double-blind, placebo-controlled, multicenter trial
    European Heart Journal, 2013
    Co-Authors: Massimo Imazio, Antonio Brucato, Riccardo Belli, Rita Trinchero, Roberto Cemin, Stefania Ferrua, Stefano Maggiolini, D. H. Spodick, Yehuda Adler

    Abstract:

    Purpose: Despite a large amount of data on recurrent Pericarditis, conclusive data are lacking to demonstrate the efficacy and safety of colchicine for the treatment of the first attack of Acute Pericarditis. The Investigation on Colchicine in Acute Pericarditis (ICAP) trial is a prospective, randomized, double-blind, placebo-controlled, multicenter trial aimed at the evaluation of the efficacy and safety of colchicine to treat Acute Pericarditis and prevent its recurrences.

    Methods: Eligible adult patients with Acute Pericarditis were randomly assigned to placebo or colchicine (0.5 mg twice daily for 3 months for patients>70kg or 0.5 mg once daily if ≤70kg) in addition to conventional anti-inflammatory therapy with aspirin or ibuprofen in a multicenter, double-blind, placebo-controlled trial. The primary study outcome was incessant/recurrent Pericarditis within 18 months. Secondary outcomes were symptoms persistence at 72 hours, remission within 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and constrictive Pericarditis.

    Results: Of the 240 randomly assigned participants (mean age 52.1±16.9 years, 60% males), 65 patients (27.1%) reached the primary outcome: incessant/recurrent Pericarditis within 18 months was 16.7% in the colchicine group and 37.5% in the placebo group (relative risk reduction 0.56 95% CI 0.30-0.72; number needed to treat-NNT 4). Colchicine reduced symptoms persistence at 72 hours (respectively, 19.2% vs. 40.0%; p=0.001), number of recurrences, hospitalizations (respectively, 5.0% vs. 14.2%; p=0.016), improved the remission rate at 1 week (respectively, 85.0% vs. 58.3%; p

    Free Register to Access Article

  • colchicine for Acute Pericarditis results from the investigation on colchicine in Acute Pericarditis icap a prospective randomized double blind placebo controlled multicenter trial
    European Heart Journal, 2013
    Co-Authors: Massimo Imazio, Antonio Brucato, Riccardo Belli, Rita Trinchero, Roberto Cemin, Stefania Ferrua, Stefano Maggiolini, D. H. Spodick, Yehuda Adler

    Abstract:

    Purpose: Despite a large amount of data on recurrent Pericarditis, conclusive data are lacking to demonstrate the efficacy and safety of colchicine for the treatment of the first attack of Acute Pericarditis. The Investigation on Colchicine in Acute Pericarditis (ICAP) trial is a prospective, randomized, double-blind, placebo-controlled, multicenter trial aimed at the evaluation of the efficacy and safety of colchicine to treat Acute Pericarditis and prevent its recurrences.

    Methods: Eligible adult patients with Acute Pericarditis were randomly assigned to placebo or colchicine (0.5 mg twice daily for 3 months for patients>70kg or 0.5 mg once daily if ≤70kg) in addition to conventional anti-inflammatory therapy with aspirin or ibuprofen in a multicenter, double-blind, placebo-controlled trial. The primary study outcome was incessant/recurrent Pericarditis within 18 months. Secondary outcomes were symptoms persistence at 72 hours, remission within 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and constrictive Pericarditis.

    Results: Of the 240 randomly assigned participants (mean age 52.1±16.9 years, 60% males), 65 patients (27.1%) reached the primary outcome: incessant/recurrent Pericarditis within 18 months was 16.7% in the colchicine group and 37.5% in the placebo group (relative risk reduction 0.56 95% CI 0.30-0.72; number needed to treat-NNT 4). Colchicine reduced symptoms persistence at 72 hours (respectively, 19.2% vs. 40.0%; p=0.001), number of recurrences, hospitalizations (respectively, 5.0% vs. 14.2%; p=0.016), improved the remission rate at 1 week (respectively, 85.0% vs. 58.3%; p<0.001), and prolonged time to first recurrence. Corticosteroid use (OR 4.17, 95% CI 1.28 to 13.53; p=0.018), and C-reactive protein elevation at presentation (OR 3.15, 95% CI 1.05 to 9.49; p=0.041) were independent risk factors for recurrences in multivariable analysis. Overall adverse effect rates were similar in the study groups (respectively, 11.7% in the colchicine group and 10.0% in the placebo group; p=0.836) as well as withdrawal rates (respectively, 11.7% vs. 8.3%; p=0.519). No serious adverse effects were observed. Conclusions: The ICAP trial is the first multicenter, double-blind, randomized trial to show the efficacy and safety of colchicine as an adjunct to conventional anti-inflammatory therapy to halve incessant/recurrent Pericarditis within 18 months, reduce the number of recurrences, and prolong the time to subsequent recurrence after a first episode of Acute Pericarditis.

    ClinicalTrials.gov [NCT00128453][1].

    [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00128453&atom=%2Fehj%2F34%2Fsuppl_1%2F877.atom

    Free Register to Access Article

  • Risk of Constrictive Pericarditis After Acute Pericarditis
    Circulation, 2011
    Co-Authors: Massimo Imazio, Antonio Brucato, Silvia Maestroni, Davide Cumetti, Riccardo Belli, Rita Trinchero, Yehuda Adler

    Abstract:

    Background—Constrictive Pericarditis (CP) is considered a rare, dreaded possible complication of Acute Pericarditis. Nevertheless, there is a lack of prospective studies that have evaluated the specific risk according to different etiologies. The aim of this study is to evaluate the risk of CP after Acute Pericarditis in a prospective cohort study with long-term follow-up. Methods and Results—From January 2000 to December 2008, 500 consecutive cases with a first episode of Acute Pericarditis (age, 51±16 years; 270 men) were prospectively studied to evaluate the evolution toward CP. Etiologies were viral/idiopathic in 416 cases (83.2%), connective tissue disease/pericardial injury syndromes in 36 cases (7.2%), neoplastic Pericarditis in 25 cases (5.0%), tuberculosis in 20 cases (4.0%), and purulent in 3 cases (0.6%). During a median follow-up of 72 months (range, 24 to 120 months), CP developed in 9 of 500 patients (1.8%): 2 of 416 patients with idiopathic/viral Pericarditis (0.48%) versus 7 of 84 patients…

    Free Register to Access Article